Pharmafile Logo
Pharmafocus logo
Advanced Search

Janssen

Showing 15 posts of 275 posts found.

darzalex

NICE meets Janssen halfway over Darzalex

January 18, 2018
Medical Communications, Sales and Marketing J&J, JJ, Janssen, biotech, darzalex, drugs, pharma, pharmaceutical

NICE rejected Janssen’s Darzalex (Daratumumab) back in March last year, concluding that it wasn’t able to accurately determine the efficacy …

News
novartis_outside_1

Novartis debuts new data showing Cosentyx’s superiority over Janssen’s Stelara in psoriasis

January 16, 2018
Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma

Novartis has lifted the curtain on new data comparing the efficacy of Cosentyx (secukinumab) to Janssen’s Stelara (ustekinumab) in achieving …

News

J&J’s Darzalex cuts risk of disease progression and death by 50%, new study shows

December 13, 2017
Research and Development Genmab, J&J, JJ, Janssen, Johnson & Johnson, darzalex, multiple myeloma, pharma

Johnson and Johnson has revealed data which demonstrates that Darzalex (daratumumab), when combined with a regimen of bortezomib, melphalan and …

News
shutterstock_273326141

Partnerships hold the key to making HIV history

November 20, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, Janssen, pharma

Brian Woodfall, Global Head of Late Development, Infectious Diseases at Janssen, explains why a future without HIV can only be …

Feature
janssen_latest_logo_on_sign_closer

Janssen’s Stelara shows improvement in Crohn’s symptoms within one week, new findings reveal

October 30, 2017
Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma

Janssen has unveiled new data on Stelara (ustekinumab) in the treatment of patients with moderately to severely active Crohn’s disease …

News

J&J’s third quarter: The good and the bad

October 18, 2017
Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Janssen, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical

It was a mixed bag for Johnson & Johnson on its announcement of third quarter results. It could largely be …

News
janssen_latest_logo_on_sign

FDA expands Janssen’s Stelara to cover adolescent psoriasis patients

October 16, 2017
Sales and Marketing FDA, Janssen, Stelara, pharma, psoriasis

Janssen has announced that the FDA has approved an expanded indication for its psoriasis therapy Stelara (ustekinumab) for the treatment …

News
bayer_cross_2

Bayer forced to halt huge study into key drug

October 6, 2017
Medical Communications, Research and Development Bayer, Janssen, Xarelto, biotech, drugs, pharma, pharmaceutical

Bayer, and development partner Janssen, have been forced to stop a Phase 3 trial looking at expanding the indication of …

News
janssen_latest_logo_on_sign_closer

Janssen reveals positive CHMP opinion, long-term data for psoriasis drug guselkumab

September 19, 2017
Manufacturing and Production, Research and Development, Sales and Marketing EMA< CHMP, Janssen, guselkumab, pharma, pharmaceuticals

Janssen has announced that its psoriasis drug guselkumab has been awarded a positive opinion by the EMA’s Committee for Medicinal …

News
640px-sq_lethal_injection_room

Janssen opposes use of its drug in state execution

August 23, 2017
Medical Communications, Research and Development, Sales and Marketing Janssen, etomidate, life sciences, pharma, pharmaceutical

Janssen has spoken out against plans to use an anaesthetic drug it invented over 50 years ago to execute prisoners, …

News
icr

Scientists discover ‘Achilles’ heel’ of oesophageal cancer

August 23, 2017
Research and Development ICR, Janssen, biotech, drugs, pharma, pharmaceutical

Researchers from The Institute of Cancer Research have potentially found a new use for Imbruvica, after discovering a weakness in …

News
janssen_latest_logo_on_sign

FDA turns down Janssen’s sirukumab for rheumatoid arthritis

August 3, 2017
Sales and Marketing FDA, Janssen, drugs, life sciences, medicine, pharma, pharmaceuticals, rheumatoid arthritis, sirukumab

Janssen has announced that it has suffered a knockback to its plans to commercialise sirukumab in the US in the …

News
janssen_latest_logo_on_sign

Janssen single tablet regimen shows Phase 3 success in HIV

July 26, 2017
Research and Development HIV, Janssen, biotech, healthcare, pharma, pharmaceuticals

The latest Phase 3 data investigating Janssen’s darunivir in the treatment of human immunodeficiency virus (HIV-1) showed that the drug …

News

Monthly injectable HIV treatment proves as effective as traditional daily pill regimen

July 24, 2017
Research and Development, Sales and Marketing AIDS, HIV, Janssen, ViiV Healthcare, biotech, drugs, pharma, pharmaceuticals

New early trial data suggests that current daily HIV pill regimens could be replaced with injections which slowly release medication …

News

J&J uses FDA Priority Review Voucher to snag psoriasis approval

July 14, 2017
Medical Communications, Sales and Marketing Janssen, Johnson & Johnson, Tremfya, biotech, drugs, pharma, pharmaceutical

The FDA has handed out another approval, as the agency now easily surpasses last year’s figure of 22 already, this …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024